---
document_datetime: 2023-09-21 21:15:43
document_pages: 35
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/telzir-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: telzir-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 77.5129678
conversion_datetime: 2025-12-27 17:44:41.150439
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Telzir

Procedural steps taken and scientificinformation after the authorisation

| Application number   | Scope                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued²/ amended on   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------------|---------------------------------|-----------|
| IG/1531              | C.I.z -Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation | 19/08/2022                          |                                           | SmPCand PL                      |           |
| N/0109               | Minorchangeinlabellingorpackageleafletnot connectedwith the SPC(Art.61.3Notification)  | 23/09/2021                          | 18/03/2022                                | PL                              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IG/1411            | A.7-Administrativechange-Deletion of manufacturingsites                                                                                                                                                        | 09/09/2021   | n/a        |                 |                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|--------------------------------|
| PSUSA/1470/ 202010 | PeriodicSafetyUpdateEUSingleassessment- fosamprenavir                                                                                                                                                          | 10/06/2021   | n/a        |                 | PRACRecommendation-maintenance |
| IG/1360            | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                        | 02/03/2021   | 18/03/2022 | Annex II and PL |                                |
| IA/0107            | A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                         | 02/03/2021   | 18/03/2022 | AnnexII and PL  |                                |
| IG/1326            | B.lL.b.2.c.1 -Change toimporter,batchrelease arrangements andqualitycontroltestingoftheFP- Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Notincludingbatchcontrol/testing | 18/01/2021   | n/a        |                 |                                |
| IG/1332            | B.ll.b.2.c.1-Change toimporter,batchrelease arrangementsandqualitycontroltestingoftheFP Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Notincludingbatchcontrol/testing    | 18/01/2021   | n/a        |                 |                                |
| IG/1307            | A.5.b-Administrative change-Changein the name and/oraddressofamanufacturer/importerofthe finished product, including quality control sites (excludingmanufacturerforbatchrelease)                              | 08/01/2021   | n/a        |                 |                                |
| WS/1951            | Thiswasanapplicationforavariationfollowinga worksharingprocedure accordingtoArticle20of                                                                                                                        | 03/12/2020   | 09/03/2021 | SmPC and PL     |                                |

<div style=\"page-break-after: always\"></div>

|           | CommissionRegulation(EC)No1234/2008. C.I.z-Changes(Safety/Efficacy)ofHumanand VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                         |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0101   | B.ll.c.3.z-Change in source of an excipientor reagentwithTSErisk-Othervariation                                                                                                                                                                                                                                  | 03/08/2020 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                   |
| IG/1237   | A.1-Administrativechange-Changeinthename and/oraddressoftheMAH                                                                                                                                                                                                                                                   | 11/06/2020 | 09/03/2021 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                   |
| IG/1210/G | Thiswasanapplicationforagroupofvariations. A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                        | 18/03/2020 | 09/03/2021 | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0098   | B.I.d.1.a.4-StabilityofAS-Changeinthere-test period/storageperiod-Extensionorintroductionofa re-testperiod/storageperiodsupportedbyrealtime data                                                                                                                                                                 | 09/08/2019 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                   |
| I/0094/G  | This was an applicationfora group of variations. Updateofsections4.3and4.5oftheSmPCinorder toimplementinformationona drug-druginteraction betweenfosamprenavir(with orwithoutritonavir) andtheantipsychoticlurasidoneandupdateof sections4.4and4.5oftheSmPCinorderto implementinformationonadruq-druqinteraction | 26/04/2019 | 18/06/2019 | SmPC and PL            | Section4.3wasupdatedtostatethatco-administrationof the antipsychotic medicinal product lurasidone and fosamprenavir/ritonavir(FPv/RTV) is contraindicated. Section4.4wasupdatedtostatethattheco-administration offosamprenavir/ritonavirwithotherantineoplastics metabolisedbyCYP3A(forexampledasatinib,nilotinib, ibrutinib,vinblastineandeverolimus)mayincrease |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | betweenfosamprenavir(with orwithoutritonavir) and various antineoplastic agents(including dasatinib,nilotinib,ibrutinib,vinblastine, everolimus),basedonanassessmentofrecent safety data.The drug-drug-interactionstable in Section4.5was alsoupdatedtoremoveactive substanceswithdrawnfromthemarketandto differentiatebetweentenofovirdisoproxil and tenofoviralafenamide.ThePackageLeafletis updated accordingly. Therequestedgroupofvariationsproposed amendmentstotheSummaryofProduct CharacteristicsandPackageLeaflet. C.I.4 -Change(s)in the SPC,Labellingor PL due to newquality,preclinical,clinicalorpharmacovigilance data C.I.4 -Change(s) in the SPC,Labelling or PL due to newquality,preclinical,clinicalorpharmacovigilance data   |            |     | concentrationsofthesemedicinalproducts,potentially increasingtheriskofadverseeventsusuallyassociated withtheseagents.Referenceismadetotherelevant productinformationforthesemedications. InSection4.5,theDDItablewasrevisedtoincludethe contraindicationwithlurasidoneduetothepotentialfor seriousand/orlife-threateningreactionsrelatedto lurasidone.Theinteractionswiththeneoplasticagents dasatinib,nilotinib,ibrutinib,vinblastineandeverolimus aremetabolisedbyCYP3Aareco-administeredwith fosamprenavir/ritonavir,plasmaconcentrationsofthese antineoplasticmedicationsmaybeincreasedandcould increasetheriskofadverseeventsusuallyassociatedwith these antineoplasticagents.Incase ofconcomitant administrationwithantineoplasticagentsmetabolizedby CYP3A,referenceshouldbemadetotherelevantproduct informationforthesemedications.Thetablewasalso updated,as drugs such asnelfinavir,telaprevirand boceprevirhavebeenwithdrawnfromthemarketandwere thereforebeendeletedfromthetable.Inaddition,asboth tenofovirdisoproxilandtenofoviralafenamide,whichdiffer intheirpharmacokineticproperties,areusedasprodrugs oftenofovir,thedesignation\"tenofovir\"hasbeenupdated todifferentiatebetweenthetwoprodrugs.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0097 | B.lL.b.2.a-Change toimporter,batchrelease arrangements andqualitycontroltestingoftheFP- Replacement/additionofasitewherebatch                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 27/02/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                    | control/testingtakesplace                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| IAIN/0096          | B.ll.b.2.c.1-Changetoimporter,batchrelease arrangementsandqualitycontroltestingoftheFP- Replacementoradditionofamanufacturer responsibleforimportationand/orbatchrelease- Not including batch control/testing                                                                                                                                                                                                                                                                                                  | 05/02/2019 | 18/06/2019 | Annex II and PL        |                                |
| IAIN/0095          | C.I.z-Changes(Safety/Efficacy)ofHumanand VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                            | 24/10/2018 | 18/06/2019 | SmPC                   |                                |
| T/0093             | TransferofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 11/09/2018 | 28/09/2018 | SmPC, Labelling and PL |                                |
| PSUSA/1470/ 201710 | PeriodicSafetyUpdateEUSingleassessment- fosamprenavir                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 14/06/2018 | n/a        |                        | PRACRecommendation-maintenance |
| IA/0092/G          | Thiswasanapplicationforagroupofvariations. B.I.a.3.a-Changeinbatch size(includingbatchsize ranges)ofASorintermediate-Upto10-fold increasecomparedtotheoriginallyapprovedbatch size B.1.b.1.d-Change in the specificationparameters and/orlimitsof anAs,starting material/intermediate/reagent-Deletionofanon- significantspecificationparameter(e.g.deletionof anobsoleteparameter) B.I.b.1.d-Change in the specificationparameters and/orlimitsof anAs,starting material/intermediate/reaqent-Deletionofanon- | 23/05/2018 | n/a        |                        |                                |

<div style=\"page-break-after: always\"></div>

|           | significantspecificationparameter(e.g.deletionof anobsoleteparameter)                                                                                           |            |            |                        |                                                                                                                                                                                                                                                                                                                |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0089    | C.I.4 -Change(s)in the SPC,Labelling or PL due to new quality,preclinical,clinical orpharmacovigilance data                                                     | 18/01/2018 | 28/09/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                |
| IB/0090   | B.Il.z-Quality change-Finishedproduct-Other variation                                                                                                           | 15/12/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                |
| IB/0088   | C.1.11.z -Introduction of, or change(s)to,the obligations and conditionsofa marketing authorisation,includingtheRMP-Othervariation                              | 27/07/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                |
| N/0087    | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                             | 10/03/2017 | 28/09/2018 | Labelling              |                                                                                                                                                                                                                                                                                                                |
| IAIN/0086 | B.IV.1.a.1-Change of a measuring or administration device-Additionorreplacementofadevicewhichis not anintegratedpartoftheprimarypackaging- Devicewith CEmarking | 16/12/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                |
| 1/0082    | C.I.4 -Change(s)in the SPC,Labelling orPL due to newquality,preclinical,clinicalorpharmacovigilance data                                                        | 25/02/2016 | 04/04/2016 | SmPC and PL            | Co-administrationofparitaprevirand fosamprenavir/ritonaviriscontraindicateddueto the expectedincreaseofparitaprevirexposureandthelackof clinicaldata assessing themagnitudeofthisincrease.Co- administrationwithsimepreviranddaclatasvirisnot recommended(duetoanincreaseofsimeprevirand daclatasvirexposure). |
| IB/0085   | C.I.z -Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                          | 21/12/2015 | 04/04/2016 | SmPCandPL              |                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IAIN/0084          | B.ll.b.2.c.1 -Change toimporter,batchrelease arrangements andqualitycontroltestingoftheFP- Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Not including batch control/testing                                                                                                                                                                           | 09/12/2015   | 04/04/2016   | AnnexII and PL   |                                |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------|--------------------------------|
| IB/0083/G          | This was an applicationfora group of variations. A.7-Administrative change-Deletion of manufacturingsites B.I.a.1.z-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAs-Other variation B.I.b.1.c-Changein thespecificationparameters and/or limits of an As, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits | 11/11/2015   | n/a          |                  |                                |
| IB/0081            | B.Il.d.1.z-Changein thespecificationparameters and/orlimitsofthefinishedproduct-Othervariation                                                                                                                                                                                                                                                                                              | 17/08/2015   | n/a          |                  |                                |
| PSUSA/1470/ 201410 | PeriodicSafetyUpdateEUSingleassessment- fosamprenavir                                                                                                                                                                                                                                                                                                                                       | 11/06/2015   | n/a          |                  | PRACRecommendation-maintenance |
| WS/0645            | Thiswasanapplicationforavariationfollowinga worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008.                                                                                                                                                                                                                                                           | 23/04/2015   | 04/04/2016   | SmPC and PL      |                                |

<div style=\"page-break-after: always\"></div>

|         | WHOguidelinesonbreastfeeding.ThePackage Leaflet has been updated accordingly. In addition, theWsAhastakentheopportunitytopromote consistencyacrossproductsbyupdatingwhere relevant (i.e. for Trizivir, Combivir, Lamivudine/ZidovudineViv and Triumeq),the pharmacokineticstatementsinsection4.6ofthe SmPCtoreflectthemostrecentlyapprovedwording forthe components abacavirand lamivudine(Kivixa EMEA/H/C/581/R/0051 and Epivir EMEA/H/C/107/II/0084). C.I.4 -Change(s) in the SPC,Labelling orPL due to newquality,preclinical,clinicalorpharmacovigilance data   |            |            |           |                                                                                                                                                                                                                                                                                                    |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0078  | C.I.4 -Change(s)in the SPC,LabellingorPL due to newquality,preclinical,clinical orpharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 23/10/2014 | 05/05/2015 | SmPCandPL | Nodosage adjustmentoffosamprenavirordolutegraviris recommended uponconcomitantadministrationofthetwo basedonobservedexposure-responserelationshipsof clinical data.Cautionis warranted andclinical monitoringis recommendedwhenthesecombinations aregivenin integraseinhibitor-resistant patients. |
| IG/0438 | C.I.8.a-Introductionof or changestoa summary of Pharmacovigilancesystem-ChangesinQPPV (including contactdetails)and/orchangesinthe PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/05/2014 | n/a        |           |                                                                                                                                                                                                                                                                                                    |
| IA/0076 | B.I.b.1.d-Change in the specification parameters and/or limits of an As, starting material/intermediate/reagent-Deletionofanon- significantspecificationparameter(e.g.deletionof                                                                                                                                                                                                                                                                                                                                                                                    | 07/05/2014 | n/a        |           |                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | anobsoleteparameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0544 | This was an applicationforavariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.4oftheSmPCwitharevised wordingontheriskoftransmissionasrequestedby the CHMP.The PL has beenupdated accordingly.In addition,minorcorrectionsaremadetotranslations and aneditorial changeisimplementedinTrizivirPL. C.I.z-Changes(Safety/Efficacy)ofHumanand                                                                   | 25/04/2014 | 05/05/2015 | SmPCand PL  | Thewarningsinproductinformationregarding theriskof transmissionhavebeenupdated asrequested bytheCHMP inaclasslabellingrequestadoptedinDecember2013. MinorcorrectionsaremadetotranslationsofCombivir SmPCinDanishandPLinFinnishandSlovenian,Celsentri SmPC and PL in Finnish and Hungarian, Telzir PL in Finnish, Tivicay SmPC in Dutch.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1/0074  | UpdateofSmPCsections4.8and5.1withadditional informationonsafety,antiviralresponseand treatmentresistanceinHIV-1infectedpaediatric subjects,based onresultsof studiespreviously submittedaspost-authorisationmeasures.In addition,theProductinformationisbeingupdated to thelatestQRDtemplateversionandeditorial changesareimplementedinSmPCsections4.4,4.8 and 5.1. C.I.4 -Change(s) in the SPC,Labelling orPL due to newquality,preclinical,clinicalorpharmacovigilance data | 25/04/2014 | 05/05/2015 | SmPC and PL | IntegratedsafetydatafromStudyAPV29005(Week24 results)andStudyAPV20003(Week168results),together withWeek48datafromStudiesAPV29005andAPV20002 demonstratedthatRTV-boostedFPVwasgenerallywell- toleratedinchildren4weeksto18yearsof age.Nonew safetyconcernshavebeenidentified.TheCHMPconfirmed thatsafetyprofileinpaediatricpatientsisconsidered comparabletothatofadultsalthoughvomitingoccurred morefrequentlyamongstpaediatricpatients. Usingthesnapshotanalysis,proportionsofsubjectsin studyAPV29005achieving<400copies/mLatWeek48 were53%and63%inthe6-<12yearolds and12-18year oldsrespectively,indicating an adequateantiviral response giventhatthepopulationincluded PI-naive andPI/ART- experiencedsubjects.Animmunologicresponse,as indicatedbyincreasesinabsoluteCD4+cellcountswas |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                                | demonstrated.Asexpected,therateofvirologicalfailures washigherinPI-experiencedsubjects(56%)thanPI-naive subjects(19%).The mutationalprofile was similarbetween children and adults.                                                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0073 | Toincludeconcomitantuseofquetiapineas a contra-indicationinSmPCSection4.3andupdate tableinSmPCsection4.5withinformationon interactionswithquetiapine,inlinewiththeclass labellingrequestforproteaseinhibitors.ThePackage Leafletis updatedaccordingly.Inaddition,thelistof local representativesinthePLis updated,minor linguisticimprovementsimplementedinSmPC and PL,instructionsinthePL on disposal ofTelziraligned withQRDtemplateandacorrectionmadeinthe FinnishtranslationofSmPCsection4.8. C.I.z -Changes(Safety/Efficacy)of Human and | 18/10/2013 | 20/11/2013 | SmPCandPL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IG/0295 | C.I.z-Changes(Safety/Efficacy)ofHumanand VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 29/04/2013 | n/a        |                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| WS/0338 | Thiswas an applicationforavariationfollowinga worksharingprocedure accordingtoArticle20of CommissionRegulation(EC)No1234/2008. Updateof sections4.4 and4.8oftheSmPCinorder toexpandexistingwarningaboutimmune reactivationsyndromewithinformationon autoimmunedisorders.ThePackageLeafletis updated accordingly.                                                                                                                                                                                                                              | 21/02/2013 | 26/03/2013 | SmPC,Annex I, Labelling and PL | ThereviewperformedbytheMarketingAuthorisation Holderidentified75casesofdifferentautoimmune disordersoccurringin thesettingofimmunereconstitution. These included Basedow's/Graves' disease,systemic lupus erythematosus,sarcoidosis,rheumatoidarthritis, polymyositis,Guillain-Barresyndrome,Still'ssyndrome and myasthenia gravis.Cases involving zidovudine,lamivudine, abacavirandfosamprenavirwereidentified.These disordersalldevelopedwhenCD4countwasincreased or |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | Inaddition,thelistof localrepresentatives was updatedinthePackageLeaflet. Furthermore,theproductinformationisbeing broughtinlinewiththelatestQRDtemplateversion 8.3. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdueinparticulartonewquality,pre- clinical,clinicalorpharmacovigilancedata      |            |            |             | increasing andviralloadundetectable.Theautoimmune disordersresolved(orimproved) spontaneouslyorwith specifictherapyandwhileAnti-Retroviral Therapywas continued.Mostofcaseshadarelativelylateonset followingAnti-Retroviral Therapyinitiationexceptcasesof Guillain-Barresyndrome and adultonsetStill's disease.The timetoonsetrangedfrom2weeksto37months. Whileitwasrecognisedthatthenumberofcasesissmall, thelongandvariabletimetoonsetprobablycauses underreportingofsuchadversereactionsandtherefore littleisknownontheexactpathogenesisandtherisk factors.TheCHMPagreedthatinformationabout autoimmunedisordersoccurringinthecontextofimmune reconstitutionshouldbereflectedintheproduct information.                                                                                  |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0066 | Updateofsection4.5oftheSmPCwithregardtothe interactionbetweenmaravirocandfosamprenavir, includingarecommendationnottousethis combination.ThePLisbeingupdatedinaccordance. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdueinparticulartonewquality,pre- clinical,clinicalorpharmacovigilancedata | 21/02/2013 | 26/03/2013 | SmPC and PL | Datafromtwointeractionstudiesinvestigatingtheeffectof maraviroconfosamprenavir/rtvandviceversawere presented.Bothdrugswereadministeredtosteadystate levels.Theresultsobtainedinthetwostudieswere contradictorywithregardtotheeffectoffosamprenavir/rtv onmaraviroc:studyA4001103indicatedincreased maravirocexposure,whereasthestudycOL112237 indicatedreducedmaravirocexposure.Ofnote,results fromstudyC0L112237wereavailableonlyintheformof an abstract,and theassessment was thereforelimited. Possiblereasonsforthedifferentoutcomesinthetwo studieswerediscussedbutnoobviousreasonforthe deviatingresultswasfound.Inbothstudiestheexposure ofamprenavir,theactivemetaboliteoffosamprenavir, decreasedwhenco-administeredwithmaraviroc. Consideringthatsafetyofmaravirochasbeenshownfor |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                    |            |            |      | maravirocexposureofgreatermagnitudethaninsubmitted studies,whileriskforunderexposureisregardedofamore seriousconcern,theCHMPconcludedthatthedosagefor maravirocshouldnotbereduced andwouldhavetobe maintainedat 300 mgBIDwhen given withFPV/RTV. However,thereductionseenintheplasmalevelsfor amprenavirwhenFPv/RTVisco-administeredwithMVC 300mgBID(Cminreducedby36%)maybe clinically relevant,thereforetheCHMPsupportednottorecommend this combination.                                                          |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0069/G | This was an applicationfora group of variations. B.I.b.1.z-Changein the specificationparameters and/orlimitsof anAs,starting material/intermediate/reagent-Othervariation B.I.a.2.a-Changes in the manufacturing process of theAs-Minorchangeinthemanufacturingprocess oftheAS                                                                     | 29/11/2012 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1/0068    | Updateof sections4.2and5.2oftheSmPC regarding dose adjustmentinpatientswithmoderate hepaticimpairmentasrequested by CHMPafter assessmentofafollow-upmeasure. C.I.3.z -Implementation of change(s)requested followingthe assessmentofanUsR,classlabelling,a PSUR,RMP,FUM/SO，datasubmittedunderA45/46, oramendmentstoreflectaCoreSPC-Other variation | 15/11/2012 | 26/03/2013 | SmPC | TheMAHhasprovidedresultsof anobservational cohort studytoexplorethesafetyandtolerabilityof fosamprenavir(FPV)/ritonavir(RTV)therapyinHIV-1 infectedpatientswithmildormoderatehepatic impairment.Due to the apparentimpossibilitytoinclude patients with moderate impaired hepatic function receiving therecommendedreduceddoseofFPV450mgBID+100 mgRTVQD,theresultsofthestudyweredeemed inconclusive.The statementsintheSmPCregardinguseof fosamprenavirinpatientswithmoderatehepatic impairmenthavebeenreinforced. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 1/0067   | Updateof sections4.4 and4.5oftheSmPCto includeinformation about drug drug interactions with Hepatitis Cvirus (HCV)proteaseinhibitors.The PL is updated accordingly. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdueinparticulartonewquality,pre- clinical,clinical orpharmacovigilancedata                                                                                                                                                                                                                                                                                                                                                                                                            | 20/09/2012   | 23/10/2012   | SmPC and PL   | Basedonthereviewoftheavailabledataon pharmacokineticandsafety,theCHMPconsideredthe inclusionofinformationrelatedtodrug-druginteractions withHepatitisCvirus(HcV）proteaseinhibitors,telaprevir and boceprevir,acceptable.Co-administrationof fosamprenavirwithritonavirand theHcVproteaseinhibitor telaprevirorboceprevirmayleadtosubtherapeuticlevels ofboth,fosamprenavirandtelaprevirorboceprevir, respectively.Thus,co-administrationofTelzirwith these HCVprotease inhibitorsisnotrecommended.   |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0163  | This was an application fora variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. IntroductionofanewDetailedDescriptionofthe PharmacovigilanceSystem(DDPS),followingthe transferofthemarketingauthorisation/scientific opinionfromGSKtoViivHealthcareLtd.ThisDDPS hadpreviouslybeenassessedforanotherproductof the same MAH/SOH.Annex IB of Epivir,Kivexa, LamivudineviivandTrizivirhaveconsequentlybeen updatedinlinewiththenewQRDtemplatewording fortheDDPS.InadditiontheMAHcorrectedaminor mistakeintheFrenchAnnexforEpivir. C.I.8.b-Introductionof a newPharmacovigilance system - which has been assessed by the relevant NCA/EMAforanotherproductofthesameMAH | 21/06/2012   | 21/06/2012   | Annex IⅡI     | UpdateoftheDetailedDescriptionofthe PharmacovigilanceSystem(DDPS）toviivHealthcareLtd version4datedMay2012.                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0062  | A.5.a-Administrativechange-Changeinthename and/or addressofamanufacturerresponsiblefor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/09/2011   | n/a          | Annex II and  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|        | batchrelease                                                                                                                                                                                                                                                                                                                                      |            |            | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0057 | Updateofsection4.5oftheSmPCwithraltegravir interactiondata.Thepackageleaflethasbeen updated accordingly.In addition,the MAH takesthe opportunityto revise the details of the Cyprus local representative. C.I.4-Variationsrelated to significantmodifications of theSPCdueinparticularto newquality,pre- clinical,clinicalorpharmacovigilancedata | 14/04/2011 | 23/05/2011 | SmPC and PL | TheMAHprovideddatafromtwopharmacokineticsstudies (COL111242andcOL112775study)conductedtoevaluate potentialdruginteractionbetweenraltegravirand fosamprenavir(withorwithoutritonavir),underboth fasting and fed conditions.Studies COL111242(fed condition)andcOL112775(fastingconditions)werephase I,randomised,openlabel,six-arm,three-period,balanced crossover,drug-druginteractionstudiesconductedin37 and 41healthysubjectsrespectively. Consideringtheresultswithfosamprenavir/ritonavir700 mg/100mgBIDcombinedwithraltegravir400mgBID, amprenavirGeometricMeanRatio(GMR)ratioforCmin was0,81,90%IC[0,58-1,13](fasting conditions), indicatingasignificantdecreasedexposureofamprenavir since the9o%CIwasoutsidethebioequivalencelimitsof [0,8-1,25].The decrease ofPKparametersforamprenavir infedconditionswasmoreimportantthaninfast conditions(GMRratioforCminwas0,67,90%IC[0,50- 0,90],infedconditions).withregards toraltegravir pharmacokinetics,infastconditions,whencombinedwith fosamprenavir/ritonavir(7o0mg/1o0mgBID),raltegravir Cminsignificantlydecreasedby36%witha90%CIforthe GMR[0.43-0,97].Infedconditions,whencombinedwith fosamprenavir/ritonavir(7o0mg/100mgBID),raltegravir Cminsignificantlydecreasedby54%witha90%CIforthe GMR[0.26-0,82].Inbothconditions,fastedandfed,Cmin valuessignificantlydecreased(44ng/ml and135ng/ml, respectively).Moreover,raltegravirAuc decreasedby55% and54%respectivelyinfastandfedconditioninpresence |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                       | offosamprenavir/ritonavir(7o0mg/1o0mgBID). Therefore,theriskoftreatmentfailure,notablyin experiencedpatients,cannotberuledout.TheCHMP recommendsthatthecombinationfosamprenavir/ritonavir withraltegravirshould benot-recommended.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1Ⅱ/0058 | Updateofsections4.3,4.4and4.5oftheSmPCwith information on alfuzocyn and PDE5 inhibitors drug interactions.ThePackageLeaflethasbeenupdated accordingly.AnnexIIhasbeenupdatedinlinewith thelatestQRDrecommendations.Inaddition,the MAHhastakentheopportunitytoupdatethelistof localrepresentatives. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdueinparticulartonewquality,pre- clinical,clinicalorpharmacovigilancedata | 17/03/2011 | 18/04/2011 | SmPC, Annex ⅡI and PL | Followingoral administration,fosamprenavirisrapidlyand almostcompletelyhydrolysedtoamprenavirandinorganic phosphate asitisabsorbed through the gutepithelium. Amprenavirisprimarilymetabolisedbytheliverwithless than1%excretedunchangedintheurine.Amprenavirand Ritonavirare both inhibitors of CYP3A4. However, amprenaviris alesspotentinhibitorofCYP3A4than ritonavir. TakingintoaccountthatCYP3A4istheprincipalhepatic enzymeisoform involved inthe metabolism of alfuzosin, theco-administrationofalfuzosinwithfosamprenavirand especiallyritonavir(whichis always co-administeredwith fosamprenavirasabooster),couldincreaseplasma concentrationofalfuzosinandthereforebeassociatedwith seriousadverseevent.Therefore,acontraindicationhas beenincludedintheproductinformation. Similarly,PDE5inhibitorsmetabolismisprincipally mediatedbythecytochromeP450(CYP)isoforms3A4.Co- administrationofTelzirwiththesemedicinalproductsis expected to substantiallyincrease theirconcentrations and mayresultinadverseevents.Therefore,the product informationhasbeenupdatedtoincludeacontraindication withregardstoco-administrationwithPDE5inhibitorsused inthetreatmentofpulmonaryarterialhypertensionanda warninqreqardinqco-administrationwithPDE5inhibitors |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                   | usedinthetreatmentoferectiledysfunction.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|--------------------------------------------|
| IA/0060/G | Thiswas an applicationfora groupof variations. B.lL.b.1.a-Replacementoradditionofa manufacturing sitefortheFP-Secondarypackaging site B.Il.b.1.b-Replacementoradditionofa manufacturingsitefortheFp-Primarypackaging site B.ll.b.2.b.1-Change tobatch release arrangements and quality control testing ofthe FP - Not including batchcontrol/testing B.lL.e.4.a-Change in shape or dimensionsofthe containerorclosure(immediatepackaging)-Non- sterilemedicinalproducts | 08/04/2011 | n/a | Annex II and PL   |                                            |
| IA/0059   | B.IV.1.a.1-Change of a measuringor administration device-Additionorreplacementofadevicewhichis not an integrated partof the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                  | 21/03/2011 | n/a | SmPC and Annex II |                                            |
| IB/0055/G | Thiswasanapplicationforagroupofvariations. B.I.b.2.e-Change in testprocedure for AS or startingmaterial/reagent/intermediate-Other changestoatestprocedure(includingreplacement oraddition)fortheAsorastarting material/intermediate B.1.b.2.a-Change in testprocedureforAS or startingmaterial/reagent/intermediate-Minor changesto an approved test procedure                                                                                                         | 09/11/2010 | n/a |                   |                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0056/G   | This was an applicationfora group of variations. B.I.a.1.z-Change in the manufacturerof AS orofa startingmaterial/reagent/intermediateforAs-Other variation B.Ia.1.f-ChangeinthemanufacturerofASorofa starting material/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAs-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.2.a-Changesinthemanufacturingprocessof theAS-Minorchangeinthemanufacturingprocess oftheAS B.I.a.3.a-Change in batch size(including batch size ranges)ofASorintermediate-Upto10-fold increasecomparedtothecurrentlyapprovedbatch size   | 05/11/2010   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                    |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0054     | C.I.3.a-Implementationof change(s)requested followingthe assessmentofanusR,classlabelling,a PSUR,RMP,FUM/SO,datasubmittedunderA 45/46, oramendmentstoreflectaCoreSPC-Changeswith NOnewadditionaldataaresubmittedbytheMAH                                                                                                                                                                                                                                                                                                                                                                                             | 18/10/2010   | n/a        | SmPCand PL            | Amendmentofsection4.3oftheSmPCandthe corresponding sectioninthePLforTeizirfilm-coated tabletsandoralsuspensionwithlovastatinandsimvastatin datatoharmonisesection4.3withtheSmPCofthese statins andthatofNorvir.Inadditionthefollowing annexes havebeenrevisedtomakeminoreditorialandlinguistic changeS:CS,DA,DE,EL,MT,NL,NOand RO. |
| 1/0053      | Updateofsection4.8oftheSmPCbasedonthe SmPCGuidelinerev2infulfillmentoffollowup measure.Additionally,AnnexIIhasbeenrevisedto reflectthatthePSuRis onayearly cycle.The MAH hasalsotakenthisopportunitytocorrectaminor                                                                                                                                                                                                                                                                                                                                                                                                  | 22/07/2010   | 26/08/2010 | SmPC,Annex IⅡI and PL | Thesection4.8of theSmPChasbeenfullyrevised followingtheSmPCguidelines.Howeverno additionor deletion have been proposed. TheMAH alsotooktheopportunitytorevise theAnnexIIto reflectthatthePSURisonayearlycycle.TheMAHhasalso                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | typographical errorin thePL. Theinformationonthelocalrepresentativesin Spain,PortugalandCyprushave alsobeenupdated in the PL. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdueinparticulartonewquality,pre- clinical,clinicalorpharmacovigilancedata                                                                                                                                                                |            |            |                                  | takenthisopportunitytocorrectaminortypographical error in the PL. Theinformation onthelocalrepresentativesinSpain, Portugal andCyprushave alsobeen updatedin thePL.   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0052 | C.I.3.a-Implementationof change(s)requested followingthe assessmentofanUsR,classlabelling,a PSUR,RMP,FUM/SO，datasubmittedunderA45/46, oramendmentstoreflectaCoreSPC-Changeswith NOnewadditionaldataaresubmittedbytheMAH                                                                                                                                                                                                           | 24/06/2010 | n/a        | SmPC                             |                                                                                                                                                                       |
| T/0050  | TransferofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                                                  | 22/03/2010 | 26/05/2010 | SmPC, Labelling and PL           |                                                                                                                                                                       |
| IB/0051 | Toamend theSummaryofProductCharacteristics (SPC)withetravirineinteractiondatatoharmonise section4.5oftheSPCwiththeIntelence，for consistencypurposes. InadditionAnnexIBhasbeenupdatedtoreferto version06oftheRMPwhichwasapprovedin December2009. FurthermoresomeinconsistenciesbetweenAnnexe IBforthe oralsuspensionand thetabletshave beencorrected: TheDutchPackageLeaflethasalsobeenbroughtin linewiththecurrentlyapprovedtext. | 22/04/2010 | n/a        | SmPC, Annex ⅡI, Labelling and PL |                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | C.I.3.a-Implementationof change(s)requested following the assessmentofan usR, class labelling,a PSUR,RMP,FUM/SO，datasubmittedunderA45/46, oramendmentstoreflectaCoreSPC-Changeswith NOnewadditionaldataaresubmittedbytheMAH                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0048 | UpdateoftheDetailedDescriptionofthe PharmacovigilanceSystem(DDPS)including change oftheQualifiedPersonforPharmacovigilance (QPPV).Consequently,Annex II hasbeen updated withthenewversionnumber.TheMAHtookthe opportunityofthisvariationtocorrecttheversion numberoftheRiskManagementPlan. Changes to QPPV                                                                                                                                                                    | 17/12/2009 | 20/01/2010 | Annex II    | TheDDPshasbeenupdated(version 7.2) toreflectthe changeoftheQPPVaswellastonotifyotherchangesto theDDPSperformedsincethelastapprovedversion. Consequently,AnnexⅡIhasbeenupdatedusingthe standardtextincludingthenewversionnumberofthe agreedDDPS.The CHMPconsidersthatthe PharmacovigilanceSystemasdescribedbytheMAHfulfils therequirements.                                                                                                                                                                                                                                                                                                                                                               |
| I/0044 | Updateofsection4.4andsection4.8oftheSPCto addastatementonmonitoring andmanagementof hyperglycaemiaandlipid(cholesterol/triglyceride) elevationsbasedondatafromtheFrenchHospital HIVcohort and tochangefrequency categoryof the adversedrugreactions\"bloodtriglycerides increased\"and\"bloodcholesterolincreased\"based ondatafrompostmarketingstudies(ESS100732 andAPV109141).Section4ofthePLwasupdated accordingly. UpdateofSummaryofProductCharacteristicsand Package Leaflet | 22/10/2009 | 23/11/2009 | SmPC and PL | Postmarketingdatahaveshownthattreatmentwith fosamprenavir(FPv)resultedinincreasesinthe concentrationoftriglyceridesandcholesterol.Physicians shouldthereforeberecommendedtoperformtriglyceride andcholesteroltestingpriortoinitiatingtherapywithFPV andatperiodicintervalsduringtherapy.Theprecautionary statementregardingthemonitoringofhyperglycaemiawas broughtinlinewith thiswording.Blood glucosetesting shouldbeperformedpriortoinitiatingtherapywithFPV and atperiodicintervalsduringtherapy.Basedonthe resultsoftwo2postmarketing studies(ESS100732and APVi09141）thefrequencycategoryoftheadversedrug reaction\"bloodcholesterolincreased\"wasincreasedfrom \"uncommon\"to\"very common\".Thetwolarge |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        |                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |      | postmarketing studies have demonstrated that Grade 3-4 cholesterolelevationsoccurathigherincidencesthan initiallyobservedinthethreeregistrationtrialsAPv30o01, APV30002andAPV30003.Aspostmarketingdatahave shownthattheincidenceofelevatedtriglyceridesranges from 0 to7%i.e.with a frequency categoryof\"common\". ThefrequencycategoryoftheADR\"bloodtriglyceride increased\"was downgradedfrom\"verycommon\"to \"common\".                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ⅱ/0039 | Update of section 4.5 of the SPC to include a dosing recommendationforco-administrationof fosamprenavirwithatazanavirbasedondatafrom interactionstudyAPV10018.Thesection4.5isalso updatedinlinewiththeAnnexAoftherevised Guidelineontheclinicaldevelopmentofmedicinal productsforthetreatmentofHIvinfection (CPMP/EWP/633/02,Rev.2)asrequestedbythe CHMPinJanuary2008. UpdateofSummaryofProductCharacteristics | 22/10/2009 | 23/11/2009 | SmPC | InstudyAPV10018theco-administrationof fosamprenavir/ritonavir(Fpv/r)7o0/100mg twice dailywith atazanavir(ATv)3o0mgoncedailyshowednoeffecton steadystateplasmaamprenavirconcentration;theplasma ATVAuc(0-）wasdecreasedby22%andCmaxby24%, Cminremainedunchanged,comparedtoco-administration ofATv/r300/100mgoncedaily.Overallnoclinically significantinteractionwereobservedwhenFPv/r 700/100mg twice dailyis coadministered with ATV 300 mg once daily.Therefore nodosage adjustmentis considered necessary.Thefullsection4.5hasbeentable-formatted withthreecolumnsforeachproductco-administeredwith FPV/rinaccordancewiththeguideline.Thedescriptionof theinteractionsdatafollows asinglepatternforall medicinal products co-administered with FPv/r which increasesthelegibilityandfacilitatestheuseofthe interactionsectionforthetreatingphysician asoutlinedin theguidance.Pharmacokineticsdataandrecommendations totreatingphysicianare supported byclinical studies alreadysubmittedbytheMAHandassessedbytheCHMP atthetimeoftheoriginalmarketingauthorisation applicationorsubsequentlyduringthelifecycleofFPV |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                    |            |            |                                | throughclinicalFollow-UpMeasuresandtypeIIvariation.                                                                                                                                                                                                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0045  | Tochangethe activesubstance specifications Quality changes                                                                                                                         | 24/09/2009 | 01/10/2009 |                                |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0047 | IA_38_a_Change in test procedure offinished product-minorchangetoapprovedtestprocedure                                                                                             | 18/09/2009 | n/a        |                                |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0043  | Renewalofthemarketingauthorisation.                                                                                                                                                | 19/03/2009 | 16/04/2009 | SmPC,Annex I, Labelling and PL | BasedontheCHMPreviewoftheavailableinformationand onthebasisofare-evaluationofthebenefitriskbalance, theCHMPisof the opinion thatthequality,safetyand efficacyofthismedicinalproductcontinuestobe adequatelyandsufficientlydemonstratedandtherefore consideredthatthebenefitriskprofileofTelzircontinuesto befavourable.TheCHMPrecommendstherenewalofthe MarketingAuthorisationforTelzir with unlimited validity. |
| 1/0042  | UpdateofDetailedDescriptionofthe PharmacovigilanceSystem(DDPS). Updateoforchange(s)tothepharmaceutical documentation UpdateofDDPS(Pharmacovigilance)                               | 19/02/2009 | 25/03/2009 | Annex II                       | TheDDPshasbeenupdated(version6.2)toreflectthe changeoftheQualifiedPersonforPharmacovigilance (QPPV）aswellastonotifyotherchangesto theDDPS performed sincethelastapprovedversion.Consequently, AnnexIhasbeenupdatedusingthestandardtext includingthenewversionnumberoftheagreedDDPS.                                                                                                                              |
| 1/0041  | Update of section4.2,4.3,4.4 and5.2ofthe SPC andsection2andsection3ofthePLwithdatafrom clinicalstudyAPV10017toimplementdosing recommendationinpatientswithseverehepatic impairment | 19/02/2009 | 25/03/2009 | SmPC and PL                    | Pleasereferto the scientificconclusions: Telzir-H-534-II-41-AR                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 1/0040   | Updateofsection4.8oftheSPCtoinclude \"paresthesia\"asrequested bythe CHMPin its conclusiononPSuR7dated 21August 2008.Section 4 of thePLwas updated accordingly. UpdateofSummaryofProductCharacteristicsand Package Leaflet                               | 22/01/2009   | 26/02/2009   | SmPC and PL   | IntheframeofPSuR7(covering21stOctober2007-20th April 2008)areviewoforalparaesthesia with fosamprenavirwasconducted sinceroutinesignal detection hasidentifiedthisdrug-eventpairtobeasignal.The reviewnoted theissueiscomplicatedsincefosamprenavir isusuallycoadministeredwithritonavir.Oralparaesthesia is a well recognised adverse event with ritonavirtherapy andhasbeenreportedtooccurinover25%ofpatients. Nonethelessitwasconcludedthatthereappearstobea trendtowardsoralparaesthesiaoccurringmorefrequently duringclinicaltrialswithfosamprenavircontaining regimens.Overall,as a causalassociation with fosamprenavircannotberuledout\"oralparaesthesia\"is addedto section4.8 of the SPC with a frequency category of\"common\"(most conservative approach).The section4 of the PL is updated accordingly.   |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0038   | Updateofsection4.2oftheSPCinordertoclarify thedosingrecommendationsinchildrenfurtherto theCHMPconclusiononaclinicalfollow-upmeasure (FUM049).The section3ofthePLhasbeenupdated accordingly. UpdateofSummaryofProductCharacteristicsand Package Leaflet | 20/11/2008   | 22/12/2008   | SmPC and PL   | AsaconclusionofFUM049,theCHMPconsideredthatthe dosingrecommendationsinchildrenwasconfusing.Section 4.2oftheSPCandsection3ofthePLforboththetablets andtheoralsuspensionhavebeenre-wordedtobefurther simplified andin ordertogainin clarity.Thelayoutofboth sectionshasbeenimproved.For theoralsuspensiona dosingrecommendationtableforfosamprenavirwith ritonavirhasbeeninserted.Itprovidesthevolume oforal suspensiontobeadministereddependingofthebody weight.Thetableeasesthereadabilityandclarifythe recommendationstothetreatingphysicians.                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| I/0037   | Updateofsection4.3andsection4.5oftheSPCto implementtheclasslabellingtextagreedbythe CHMPinMay2008onthecombinationofrifampicin withfosamprenavirgivenwithconcomitantlow-dose ritonavir. UpdateofSummaryofProductCharacteristics                                                                                                        | 25/09/2008   | 21/10/2008   | SmPC      | In2oo5aninteractionstudyonsaquinavirboostedwith ritonavirtogetherwith rifampicininhealthyvolunteershad tobeprematurelydiscontinuedduetoanincreasedriskof hepatotoxicityassociatedwiththisco-administration.The mechanismforthisinteractionisnotfullyelucidated.Ithas beenhypothesisedthatthepredominanteffectbetweenthe inducereffectofrifampicinand theinhibitoreffectofthe boostedproteaseinhibitorsmightdependontheboosted proteaseinhibitorinvolved.Lackingtheresultsofspecific interactionstudies,theCHMPconcludedasaconservative measuretoreinforcethecontraindicationwithrifampicinin section4.4andimprovetheguidanceprovidedto physiciansregardingtheinteractionofboostedprotease inhibitorswith rifampicininsection 4.5.   |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0036   | Updateofsection4.5oftheSPCwith recommendationsregardingco-administrationof fosamprenavirandlopinavir/ritonavir(concomitant administrationofthesemedicinalproductsisnot recommended) following assessment of a clinical follow-upmeasure.ThePL has beenupdated accordingly. UpdateofSummaryofProductCharacteristics and PackageLeaflet | 26/06/2008   | 29/07/2008   | SmPCandPL | Onthebasisofpharmacokineticdataextractedfrom4 clinical studies(3in healthyvolunteers and 1 in HIV- infectedpatients)investigatingtherecommendeddosage regimensforfosamprenavirandlopinavir/ritonavirand otherregimenswithanincreaseoffosamprenavirdosage, of lopinavirdosage orofritonavirdosage,theProduct InformationofTelzirwasamended.Recommendationsand dataonco-administrationofTelzirwithlopinavirand lopinavir/ritonavirhavebeendeletedfromsection4.5of theSPCandreplacedbyanon-recommendationof concomitant useof lopinavir/ritonavirwithfosamprenavir. Section2ofthepackageLeaflethasbeenupdated accordingly.                                                                                                             |
| 1/0035   | Updateofsection5.3oftheSPCbasedondatafrom a14-dayinvestigationaloraltoxicitystudyinmale ratsasrequestedbytheCHMP.TheMAHalsotook                                                                                                                                                                                                       | 30/05/2008   | 07/07/2008   | SmPCandPL | A14-dayoraltoxicitystudywasconductedwith fosamprenavirinmaleratstoinvestigatethemechanism of thyroid-proliferativeeffectsobservedinapreviouslong-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | theopportunitytocorrectamistakein thePLfor the oral suspension. Updateof SummaryofProductCharacteristicsand Package Leaflet                                                                                           |            |            |             | termcarcinogenicitystudyinrats.The effects of fosamprenavir2250mg/kg/dayonhepaticUDP- glucuronosyltransferaseandcytochromeP450(CYP) activityandserumlevelsof thyroid hormones,i.e. thyroxine (T4), triiodothyronine(T3),and thyroid stimulating hormone (TSH) were evaluated.A time-related decreaseinT4levelswasobserved,withsubsequent increaseinTSHlevels.Inparallel,therewereincreasesin liverweight,hepatocellularhypertrophy,andincreased hepaticgeneexpressionofT4-conjugatingenzymes and transportproteins.Theseresultsindicatethatthyroid follicularcelladenomasobservedinratsarerelatedto hepaticenzymeinduction andsubsequentincrease of hepaticclearanceofthyroxine.Theclinicalrelevanceof these findingsis unknown.   |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0034 | Updateofsection4.5oftheSPCwithparoxetin interaction data.The PL was updated accordingly. Additionally,the contactdetailsforLatvia were updated in the PL. Updateof SummaryofProductCharacteristicsand Package Leaflet | 24/04/2008 | 20/06/2008 | SmPC and PL | Adruginteractionstudybetweenparoxetine20mgonce dailyand fosamprenavir(pro-drug ofamprenavir)/ritonavir 700/1oomgtwicedailywasdonetoassesstheeffectof coadministrationofthesemedicinalproducts.Theexposure ofparoxetinewasdecreasedbyaround5o%when paroxetinewascoadministeredwith fosamprenavir/ritonavir.However,therewasnoeffectof paroxetineonamprenavirorritonavir.Themechanismfor theseeffectsiscurrentlyunknown,buttheproduct informationwasupdatedtoreflectthestudyresults. Subjectstakingthesemedicinestogetherwill beclosely monitoredand,if needed,the doctorwill adjustthe paroxetine dose.                                                                                                                             |
| 1/0033 | Updateofsection5.1oftheSPCwithin-vivo resistancedatabasedonrelevantclinicaltrialswith                                                                                                                                 | 24/04/2008 | 20/06/2008 | SmPC        | Basedonin-vivofosamprenavirresistancestudiesin antiretroviraltherapy(ART)-naive,proteaseinhibitors(PI)-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | theritonavirboostedfosamprenavirregimen. UpdateofSummaryofProductCharacteristics                                                                                                                                                                                                       |            |            |           | naive，PIexperiencedandARTexperiencedpatients,the productinformationwasupdated.Nodifferenceswere observedbetweentheresistancemutationsselectedby boostedandunboostedfosamprenavirandtheanalysisof thevirologicalfailuresamplesdefinedfourmainresistance pathways in ART-naive orPI-naivepatients.Similar resistancepatternswereobservedinthepaediatricpatients comparedwiththeadults.ThewordingonPIexperienced patientswasalsoupdated;certainmutations were deleted astheywerenotpresentorwerenottreatmentemergent (i.e.,werealreadypresentinitiallybeforetreatment).   |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I/0032 | Updateofsections4.4 and4.5of theSPCbasedon aninteractionstudyoffosamprenavir/ritonavirwith phenytoin.Consequently,thePLwasupdatedas well. UpdateofSummaryofProductCharacteristics and PackageLeaflet                                                                                   | 24/01/2008 | 28/02/2008 | SmPCandPL | Adrug-druginteractionstudy,performedinhealthy subjects,hasshownthattheco-administrationof fosamprenavir/ritionavirtwicedaily7o0/1o0mgwith phenytoin300mgoncedaily: -slightlyincreased theexposuretoamprenavir,which is notexpectedtobeclinicallyrelevant, -slightlydecreased theexposuretophenytoin. Itisthereforerecommendedthatphenytoinplasma concentrationsshouldbemonitoredandthephenytoin dosesshould beadjusted as appropriate.Thesefindings werereflectedintheProductInformation.                                                                              |
| I/0031 | Updateofsection4.8oftheSPCfurthertoareview ofangioedemacasescarriedoutbytheMAHto includethe adversereactionangioedema. Consequently,thePLwasupdated aswell.In addition,theMAHhastaken the opportunityto update thePLfurtherto user testing. UpdateofSummaryofProductCharacteristicsand | 13/12/2007 | 18/01/2008 | SmPCandPL | Fosamprenavir(Fpv)containsa sulphonamide moiety. Publishedliteratureacknowledgesthatsulphonamideshave beenassociatedwithallergicreactions.Angioedemais oftenafeatureofallergicreactions.Asof20April2007，39 reportsofangioedemawereidentifiedforFPvfromthe MAH'sworldwidesafetydatabase.Ninereportswere classifiedaskey casesofwhich4wereassessed as providingthebestevidenceofacausalrelationship(e.g.                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | PackageLeaflet                                                                                                                                                                                                                   |            |            |                       | eventsresolvedwhenFPVwasdiscontinued+compatible timetoonset+occurred withrash).Basedonevidence from clinical trials,the frequency categoryfor this adverse reactionwascalculatedas\"uncommon\".                                                                                                                                                                                                                                                                       |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0028  | Updateoftheresistancedatainsection5.1ofthe SPCbasedonacumulativesummaryofallemergent mutationsobservedduringclinicaltrialswith unboostedandboostedfosamprenavirinpreviously ProteaseInhibitor-naiveaswellasexperienced patients. | 18/10/2007 | 21/11/2007 | SmPC                  | Furthertotheannualreviewonresistanceandcross- resistancecarriedoutbytheMarketingAuthorisation Holder,theinformationintheSPChasbeenupdatedwith mutationsobservedduringclinicaltrialsinadultand paediatricpatientswithunboosted andboosted fosamprenavirinpreviouslyPI-naiveaswellasexperienced patients.                                                                                                                                                             |
| 1/0027  | Updateofsections4.4and4.5oftheSPCbasedona methadone drug-drug interaction study with fosamprenavir/ritonavir.ThePL is updated accordingly. UpdateofSummaryofProductCharacteristics and PackageLeaflet                            | 20/09/2007 | 23/10/2007 | SmPC and PL           | Aninteractionstudyinhealthyvolunteerswhowereona stablemethadone substitution therapyand whoweregiven fosamprenavir/ritonavirshowedthatneitherR-methadone (whichistheactivemoietyinmethadonesubstitution therapy)noramprenavir(whichistheactivemoietyin fosamprenavir/ritonavirtherapy)blood levelswereaffected toaclinicallyrelevantextentbytheinteractionofthe testedcompounds.Thisinformationwasreflectedinan updateofboththeinteractionsectionintheSPCandthe PL. |
| IA/0030 | IA_o5_Changeinthenameand/oraddressofa manufacturerofthefinishedproduct                                                                                                                                                           | 14/09/2007 | n/a        | Annex II and PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1/0018  | ExtensionofthetherapeuticindicationofTelzirin combinationwithritonavirforthetreatmentof HumanImmunodeficiencyVirusType1 (HIV-1) infectedadultsincombinationwithother                                                             | 19/07/2007 | 13/09/2007 | SmPC,Annex IⅡI and PL | ForfurtherinformationpleaserefertotheScientific Discussion: EMEA-H-534-II-18-AR                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | antiretroviralmedicinalproductstoinclude adolescents andchildrenof6yearsand above. ExtensionofIndication                                                                                                         |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0029 | IB_14_b_Changeinmanuf.ofactivesubstance withoutPh.Eur.certificate-newmanufacturer                                                                                                                                | 08/08/2007 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1/0021  | Updateofsections4.3,4.4and4.5ofSPCand section2ofthePLasregardstheinteractionofTelzir withoralandparenteralmidazolam,followinga CHMPrequestinMarch2007. UpdateofSummaryofProductCharacteristicsand PackageLeaflet | 21/06/2007 | 24/07/2007 | SmPC and PL | BasedonavailabledataforotherCYP3A4inhibitors,plasma concentrationsofmidazolamareexpectedtobe significantlyhigherwhenmidazolamisgivenorallythan whenitisinjected.Therefore,theco-administrationof Telzir/ritonavirwithorallyadministeredmidazolamis contraindicated,whereascautionisrecommendedwhen Telzir/rtvis co-administratedwithinjectionofmidazolam. If Telzir/rtvis co-administeredwithinjectablemidazolam,it shouldbedoneinanintensivecareunit(Icu)orsimilar settingwhichensures closeclinical monitoring and appropriatemedicalmanagementincaseofrespiratory depressionand/orprolongedsedation.Dosageadjustment formidazolamshould beconsidered,especiallyifmore thanasingledoseofmidazolamisadministered.Sections 4.3,4.4and4.5oftheSPCandsection2ofthePLare updated with thisinformation. |
| IB/0022 | IB_14_b_Change in manuf.of active substance withoutPh.Eur.certificate-newmanufacturer                                                                                                                            | 06/07/2007 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1/0020  | Update of sections4.2,4.4and5.2of the SPCbased ona studyinmildlyandmoderatelyhepatically impairedpatients.Consequently,the PL is updated as well.                                                                | 24/05/2007 | 02/07/2007 | SmPCand PL  | Thisstudywasperformedtoestablishdosage recommendationsinpatients with mild ormoderate hepatic impairment.Theresultsshowedthatinthesepatients,the recommendeddailydosageneedstobereducedinorderto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | UpdateofSummaryofProductCharacteristics and PackageLeaflet                                                                                                                                                                                                                                                                                     |            |            |      | avoidhighplasmaconcentrationsofamprenavir,theactive compoundof Telzirinblood.whilesomedose recommendationscanbegivenbasedonthefindingsofthe study,itwasalsodemonstratedthatinpatientswithmild or moderate hepaticimpairmenthigh patient-to-patient variabilityofplasmaconcentrationmaybefound. Therefore,an additional warningtomonitorthesepatients whenstartingthistreatmentschedulewasaddedto the newdosagerecommendations.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0026 | IA_04_Change in name and/or addressof a manuf. oftheactive substance(noPh.Eur.cert.avail.)                                                                                                                                                                                                                                                     | 12/06/2007 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0025 | IA_11_a_Changeinbatchsizeofactivesubstanceor intermediate-up to10-fold                                                                                                                                                                                                                                                                         | 12/06/2007 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0024 | IA_04_Change in name and/or addressof a manuf. ofthe active substance(noPh.Eur.cert.avail.)                                                                                                                                                                                                                                                    | 12/06/2007 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0023 | IA_04_Changeinnameand/oraddressofamanuf. oftheactive substance(noPh.Eur.cert.avail.)                                                                                                                                                                                                                                                           | 12/06/2007 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1/0009  | Updateofsection5.1oftheSPCtoprovide recommendationswithregardstothemutation predictiveofvirologicalresponseto fosamprenavir/ritonavirandtoreviewavailablein vitroresistancedataand assessthepossibilityof cross-resistancetootherlicensedproteaseinhibitors such aslopinavir,atazanavirand tipranavir. UpdateofSummaryofProductCharacteristics | 24/01/2007 | 28/02/2007 | SmPC | Duringthe studyAPV30o01 inPI-naivesubjects treated withunboostedfosamprenavir,PI-mutationswereidentified in patients failing fosamprenavirtherapy. DuringstudiesinPI-naivepatientstreatedwithboosted fosamprenavir(studiesAPV30005(APV30002extension afterWeek48)andESS100732)PI-mutationswere identified in failing patients after 96 to 204 weeks therapy studyAPV30002PIresistance-associatedmutationsdidnot emerqebyWeek48.  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        |                                                                                                                                                                                                     |            |            |             | InstudiesinPI-experiencedpatients(APV30003andits extensionandAPv30o05),mutationsemergedinpatients with virologicalfailure. HIV-1isolateswithadecreasedsusceptibilityto amprenavir havebeenselectedduringinvitroserialpassage experiments.Reducedsusceptibilitytoamprenavirwas associatedwithvirusthathaddevelopedI50vorI84Vor V32I+I47VorI54Mmutations.Eachofthesefourgenetic patternsassociatedwithreducedsusceptibilityto amprenavirproducessomecross-resistancetoritonavirbut susceptibilitytoindinavir,nelfinavirandsaquinaviris generallyretained. There are currentlyinsuficient data on cross-resistancebetweenamprenavirandotherprotease inhibitors.Basedondatafromthirteenantiretroviralnaive patientsfailingafosamprenavircontainingregimenandon limitedinvitrodata(sitedirectedmutagenesis)the resistancepathwaysassociatedwithamprenavirproduce limitedcross-resistancetolopinavir(clinicaldata available fromthirteenisolates)while susceptibilityto atazanavir (from fourisolates)andtipranavir(from twoisolates)is generallyretained.Conversely,amprenavirretains activity againstsomeisolateswithresistancetootherPIsandthis retained activitywoulddepend onthenumber andtype of   |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0017 | Updateof sections4.4 and4.8oftheSPCand section2ofthePLtoimplementtheclasslabelling textonosteonecrosis,agreedbytheCHMPin September2006. Updateof SummaryofProductCharacteristics and PackageLeaflet | 14/12/2006 | 18/01/2007 | SmPC and PL | Cases ofosteonecrosis(deathofthebonetissueresulting from an insuficientblood supply)havebeenreportedin HIV-infectedpatientssincetheendofthe80's.Although thecauseofthisdiseasecouldbeduetomultifactors (includingthe use ofcorticosteroids,alcohol consumption, severeimmunosuppression,higherbody massindex)ithas occurredspeciallyinpatientswithHIVadvanceddisease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                        |            |            |           | and/orinpatientswithlong termuseofcombination antiretroviral therapy(CART).Further tothereview of all availabledatatheCHMPagreedthatthisinformation shouldnowbeincludedintheSPCandPLofall antiretroviralmedicinalproducts.Patientsshouldbe warnedtoseekmedicaladviceincasetheyexperiencejoint shoulderorif theyexperienced anydifficultyinmovement.                                                                                                                                                                                                                                   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0008  | Toupdatesection5.3oftheSPCwithdatafrom two carcinogenicitystudiesinmiceandrats,as requestedbytheCHMPfurtherto the assessmentof theInitialMarketingAuthorisationApplicationdossier on3June2004. UpdateofSummaryofProductCharacteristics | 14/12/2006 | 18/01/2007 | SmPC      | Informationfromlong-term carcinogenicitystudies with fosamprenavirinmice andratshavebeenincludedand replacethepreviouswordinginthepreclinicalsafety sectionthatwasbasedonamprenavirdataonly.The studiesperformedwithfosamprenavirshowedincreasesin hepatocellularadenomasandhepatocellularcarcinomasin miceandincreasesinhepatocellularadenomasandthyroid follicularcelladenomasinrats.Inrats,anincreasein interstitial cell hyperplasia inmales and anincreasein uterineendometrialadenocarcinomainfemaleswas observed. AthispointIntimetheclinicalrelevanceofthisfindingis unknown. |
| IA/0019 | IA_o7_a_Replacement/add.ofmanufacturingsite: Secondarypackagingsite                                                                                                                                                                    | 05/01/2007 | n/a        |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1/0012  | Updateofsection5.1oftheSPCwithdatafroma clinical a study of Telzir/ritonavirtwice dailyvs. lopinavir/ritonavirtwicedailyintreatmentnaive population. The abbreviation Fos for fosamprenavir hasalsobeenamendedtoFVPintheSPC.           | 16/11/2006 | 03/01/2007 | SmPCandPL | TheKLEANstudyshowedthenon-inferiorityof fosamprenavir/ritonavirtolopinavir/ritonavirina headto headcomparisonofbothproteaseinhibitorsinthis multicentre,randomised,openlabelstudy,bothin associationwiththeabacavir/lamivudine(ABC/3TC 600/300mq)fixed-dosecombinationtabletoncedaily.in                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | Inadditionsection6ofthePLwasupdatedwiththe localrepresentativesinBulgaria andRomania. Updateof SummaryofProductCharacteristics and PackageLeaflet                                                                                                                                                  |            |            |      | antiretroviralnaivepatients.Thisstudythereforereinforced thedosingrecommendationinnaivepatients,which followed the twice daily regimen in agreement with the dosingrecommendationsforantiretroviralexperienced patients.Both efficacy and safety results were comparable forbothtestedmedicinalproductsinthestudiedpopulation andfor the duration ofthis study(48weeks analysis).                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0016 | IB_14_b_Changeinmanuf.ofactivesubstance withoutPh.Eur.certificate-newmanufacturer                                                                                                                                                                                                                  | 10/11/2006 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0015 | IB_14_b_Changeinmanuf.ofactivesubstance withoutPh.Eur.certificate-newmanufacturer                                                                                                                                                                                                                  | 10/11/2006 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1/0011  | Updateofsection4.5oftheSPCinregardofthe interaction withketoconazole,asrequested bythe CHMPon7June2006,followingthe assessmentof aninteractionstudycomparingketoconazole2oomg oncedailyandfosamprenavir/ritonavir700/1o0mg twice dailyinhealthyvolunteers. UpdateofSummaryofProductCharacteristics | 21/09/2006 | 31/10/2006 | SmPC | This was a phase I, randomised,open-label,threeperiod, single sequence,drug-druginteraction studycomparing plasmaketoconazoleandamprenavirpharmacokinetics followingadministrationofketoconazole2o0mgoncedaily, fosamprenavir700mg+ritonavir100mg(twice daily)and ketoconazole 200 mg once daily+fosamprenavir700 mg twice daily+ritonavir1o0 mg twice dailyinhealthy adult volunteers. Resultsofthisstudyshowedthatketoconazole pharmacokineticparameters(essentiallyAuc)are significantlyincreasedwhenketoconazole2o0mgonce dailyisco-administeredwithfosamprenavir7o0mgtwice dailyboostedwithritonavir100mg twicedaily(exposure increasedabout2.69fold).Thustheseresultsconfirmthat fosamprenavirboostedleadstoanincreaseon ketoconazole AuC,which ismuchhigher(2.69 fold)than whatwasobservedwithamprenavirunboosted(44%).No |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                        |            |            |             | significantimpactofketoconazoleonamprenavirand ritonavirexposuresisobserved.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0010  | Updateof sections4.4 and 4.5of the SPCwith data, asrequestedbytheCHMP,ontheinteractionoforal contraceptives with fosamprenavir based on a clinical study.Consequentially,the PL has alsobeen updated toreflectthesenewdata. UpdateofSummaryofProductCharacteristicsand Package Leaflet | 21/09/2006 | 31/10/2006 | SmPC and PL | Thiswasaninteractionstudybetweenritonavir-boosted daily)andacombinationproductofethinylestradiol /norethisterone 0.035/0.5mgonce daily(anoral contraceptive)atsteadystateinhealthyfemalevolunteers. Thefindingsshowedthattheconcentrationsoftheoral contraceptive were markedlydecreased.Thisdecrease, however,doesnotnecessarilyseemtoleadto contraceptivefailure,asindicatedbythemeasured relevantfemalehormones.However,laboratoryfindingsof increasedlivertransaminaselevelstogetherwithclinical manifestationswarrantedaspecialwarningthatthis combinationmayleadtoriskofhepatictransaminase elevations. |
| IA/0014 | IA_11_a_Change in batch size of active substance or intermediate-upto10-fold                                                                                                                                                                                                           | 27/10/2006 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0013 | IA_o4_Changeinnameand/oraddressofamanuf. ofthe active substance(noPh.Eur.cert.avail.)                                                                                                                                                                                                  | 27/10/2006 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1/0007  | Updateofsection4.5oftheSPCwithnewdataon theinteractionofrifabutinandfosamprenavirbased onthewordingproposed by theCHMPon14 December2oo5furthertotheassessmentofan interaction study. UpdateofSummaryofProductCharacteristics                                                           | 23/03/2006 | 18/04/2006 | SmPC        | Thiswas a phase I, randomised,openlabel,twoperiod, two-sequence,cross-over,drug-druginteraction study conductedinhealthyadultvolunteersatonestudycentre intheUnitedStates.Itwasconductedtofurther substantiatetherecommendationofco-administrationof fosamprenavir/ritonavirwithrifabutin.Basedonthenew data,therecommendationfordosagereductionofatleast 75%forrifabutinwhenco-administeredwith                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                 | fosamprenavir/ritonavirwasmaintained. Additionally,astheresultingbloodlevelsfortherifabutin metabolite25-O-desacetylrifabutinweremuchhigherthan for rifabutin,a warning was included.This addressed the potentialofanincreaseofrifabutinrelated adverse reactions,notablyuveitis,thatareassociatedwithits metabolite.                   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0005  | Updateofsection4.5oftheSPCwithdataonthe nevirapineinteraction withfosamprenavirfurtherto theCHMPassessmentoftheclinicalinteraction study. UpdateoftheProductInformationaccordingtothe currentEMEA/QRDtemplate.Additionally,section4 ofthePackageLeaflet\"PossibleSideEffects\"has beenamendedtoimprovepatientreadability. Update of Summary of Product Characteristics, Labelling and PackageLeaflet | 26/01/2006 | 28/02/2006 | SmPC,Annex II, Labelling and PL | Theco-administrationoffosamprenavir7oomgtwicedaily +ritonavir100mgtwicedailywithnevirapine2o0mgtwice dailyincreasedplasmanevirapineAuc(0-t)by14%,Cmax by13%andCtby22%.Therefore,theCHMPconsidered thattherewasnosignificantimpactof fosamprenavir/ritonavironthenevirapinePKparameters that would justify a nevirapine dose adjustment. |
| IB/0006 | IB_12_b_01_Changeinspec.ofactive subst./agent inmanuf.ofactivesubst.-testparameterAS                                                                                                                                                                                                                                                                                                               | 16/12/2005 | n/a        |                                 |                                                                                                                                                                                                                                                                                                                                         |
| 1/0003  | To update section5.1 oftheSPCfollowing a CHMP requestdated17March2005withinformationon protein adjustedratiosofCmin/Ic50andCmin/Ic95, presentedasmedianratiosandrangesfurthertothe assessmentoftheFollow-upmeasure017.In addition,point6ofthePLissubjecttoaminor revisiontoreflectthechangeoftheMAH'snamein Poland.                                                                                | 15/09/2005 | 25/10/2005 | SmPC and PL                     | TheMAHsubmittied theratioAPVCt,ss/IC95derivedfrom studyAPV30o03intreatment-experiencedpatients.The ratioplasmaCt,ssAPV/baselineIC95adjustedforprotein bindingobtainedwiththeregimenfosamprenavir7oomg BID+RTV100mgBIDwasequalto3.21,and2.55with theregimenFAPV1400mgQD+RTV200mgQD. The median IC95valueswere0.054μg/ml[0.013-0.669],    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | UpdateofSummaryofProductCharacteristicsand PackageLeaflet                                                                                                                                                                                                                                       |            |            |             | i.e around 6-fold the IC 50values.Interestingly,the geometricmeanplasmaCminof1.74ug/mlreportedin studyAPV30003wasabovethemedianIC95values.Even thoughthesedatahavetobeinterpretedwithcautiondue to the experimental variabilityofdeterminingthisvalue (IC95), they allowto appreciate the true levelof resistance intreatment-experiencedsubjects.                                                                                                                                                                  |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0002  | Toupdatesection4.4and4.5oftheSPCwiththe claslabellingtexton\"fluticasone\"followingthe CHMPAssessmentReportonthe\"Interactionwith ritonavirboostedproteaseinhibitors andfluticasone\" dated26May2005.Point2ofthePLisamended accordingly. UpdateofSummaryofProductCharacteristicsand Package Leaflet | 27/07/2005 | 24/08/2005 | SmPC and PL | TheMAHimplementstheclasslabellingonthefluticasone propionate-ritonavirinteraction.Thisinteractionis supported bytheresultsofonemultiple-dosecrossover designclinicalstudyinhealthysubjects,conductedbyGSK inJuly-October2002(StudyFNM10004).Thisstudy aimedatevaluatingtheeffectsofseveralCYP3A4 inhibitors,including ritonavir,ketoconazole and erythromycinonsystemicconcentrationsoffluticasone after nasalinhalation.                                                                                           |
| IB/0004 | IB_10_Minor changein the manufacturingprocessof theactivesubstance                                                                                                                                                                                                                              | 10/08/2005 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1/0001  | Toupdatesection4.4and4.8oftheSPCandsection 2ofthePL，toimplementtheclasslabellingtext regarding the Immune Reactivation Syndrome, as adoptedbytheCHMPinJuly2004. UpdateofSummaryofProductCharacteristics and PackageLeaflet                                                                      | 18/11/2004 | 17/12/2004 | SmPCand PL  | Inpatientstreatedwithanytypeofcombination antiretroviraltherapy(CART), aninflammatoryresponseto indolent orresidual opportunisticinfections mayoccur, whentheimmunesystemrespondstotreatment. Inmostcases,theinflammatoryreactionstowardsthe opportunisticpathogensinquestioncannotbeforeseen sincetheopportunisticinfectionhasnotyetbeendetected/ diagnosed.If diagnosedpriortoinstitutionofCART，the treatment against the opportunistic infection (oi) is usually given priority.In particular,thisistrue for the |

<div style=\"page-break-after: always\"></div>

| complicationsmostfeared in this context;CMV-retinitis, generalisedmycobacterialinfectionsandPneumocystic cariniipneumonia.An additionalreasonfortreatingthe OI andtheHIV-infectionsequentially,isthegreatriskof adverse events (toxicity or lack of effect) due to drug interactions.Inconclusion,inmost cases,the clinical consequencesoftheawakeningimmunesysteminpatients startingARTcannotbeprevented.therefore,early recognitionanddiagnosisoftheseinflammatoryreactions areimportantintheclinicalhandlingofthepatient. Thedescriptionandtheguidelinesfortreatmentofthe numerous clinicalconditionspotentiallyarisingin associationwith thereactivationoftheimmunesystemin HIV-infectedpatients are given in the textbooks of infectiousdiseases.However,astheclinicalconditions associated with the reactivation ofthe immune system may constituteathreattothepatient,areminderofthe phenomenonisdeemedofvalueand hasbeenincludedin theSPCandPLofallantiretroviralmedicinalproducts.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|